Testing a New Imaging Agent to Identify Cancer

Inclusion Criteria:

• Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease

Note: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization [ISH]-negative, including FISH.

• Biopsy proven primary malignancy or metastatic disease

• At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocolenrollment

• Age 18 years or greater

• ECOG performance of 0-2

Exclusion Criteria:

• Creatinine > 2 times normal limit (obtained with 8 weeks of enrollment)

• AST/ALT > 2 times normal limit (obtained with 8 weeks of enrollment)

• Life expectancy < 3 months

• Pregnancy or lactation

• Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)